Form 4: Aerovate Therapeutics Executive Exercises and Sells Stock Options Under 10b5-1 Plan

Hunter Gillies, Chief Medical Officer of Aerovate Therapeutics, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 7, 2024, Hunter Gillies, the Chief Medical Officer of Aerovate Therapeutics, exercised stock options to acquire 8,975 shares of common stock at a price of $2.14 per share.
• Simultaneously, Gillies sold 8,975 shares of common stock at a price of $24.50 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 19, 2023.
• Following these transactions, Gillies directly owns 3,251 shares of common stock and holds options to purchase 116,834 additional shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There's no inherent positive or negative implication.

Positives

• The execution of options and sale of shares occurred under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company executives.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive stock activity.

Key Dates